Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
VanEck Biotech ETF (BBH)
About this ETF
The VanEck Biotech ETF (BBH) aims to closely reflect the price appreciation and income yield of the MVIS US Listed Biotech 25 Index (MVBBHTR), prior to the deduction of fees and expenses. This index monitors the aggregate performance of corporations involved in the research, manufacturing, promotion, and sale of medications derived from genetic insights and diagnostic technologies.
Price
Top 10 holdings
| Amgen Inc AMGN | 15.13% |
| Gilead Sciences Inc GILD | 12.99% |
| Vertex Pharmaceuticals Inc VRTX | 8.80% |
| Regeneron Pharmaceuticals Inc REGN | 6.54% |
| Revolution Medicines Inc RVMD | 5.20% |
| Natera Inc NTRA | 4.84% |
| Argenx Se ARGX | 4.65% |
| Iqvia Holdings Inc IQV | 4.58% |
| Alnylam Pharmaceuticals Inc ALNY | 3.76% |
| Illumina Inc ILMN | 3.39% |
Sector mix
Price chart
Returns
| 1 month | +11.68% |
| 3 months | +9.61% |
| 6 months | +5.52% |
| Year to date | +8.03% |
| 1 year | +26.88% |
| 3 years (ann.) | +9.85% |
| 5 years (ann.) | +0.14% |
| 10 years (ann.) | +7.17% |
Risk profile
| Volatility (1y, ann.) | 19.77% |
| Sharpe (1y) | 1.30 |
| Sharpe (3y) | 0.59 |
| Sortino (1y) | 2.23 |
| Max drawdown (1y) | -10.55% |
| Max drawdown (5y) | -39.99% |
| Max drawdown (full) | -72.69% |
| Beta vs S&P 500 (1y) | 0.68 |
| Correlation vs S&P 500 (1y) | 0.43 |
Technical outlook as of 2026-07-13
The Monte Carlo cone is drawn on the price chart above (Forecast overlay); RSI, MACD and the rest of the oscillators live in its indicator panels.
Full holdings
| Constituent | ISIN | Market value | Weight |
|---|---|---|---|
| Loading… | |||
Sector breakdown
Geographic exposure
Cost vs. peers
Comparison universe: 6,948 funds of the same asset class.
Cost impact calculator
Dividend history
Accumulating share class Income is reinvested inside the fund instead of being paid out. (inferred from the absence of distributions)
No distributions on record — accumulating share classes reinvest income instead of paying it out.
Splits
| 2012-02-14 | 3:1 |
ESG profile
Benchmark: average of 4,066 funds of the same asset class with derived ESG data.
Similar ETFs
| Fund | TER | AUM (USD) | Yield (TTM) | Return 1y | Sharpe 1y |
|---|---|---|---|---|---|
| Vanguard Total Stock Market ETF VTI | 0.03% | 2.30T | 1.05% | +19.93% | 1.48 |
| Vanguard S&P 500 ETF VOO | 0.03% | 1.70T | 1.07% | +19.68% | 1.49 |
| iShares Core S&P 500 ETF IVV | 0.03% | 894.38B | 1.09% | +19.68% | 1.49 |
| State Street SPDR S&P 500 ETF SPY | 0.09% | 789.23B | 1.00% | +19.71% | 1.49 |
| SPDR S&P 500 ETF Trust 1557.T | 0.09% | 789.09B | 0.49% | +37.54% | 2.26 |
| State Street SPDR S&P 500 ETF SPY.AX | 0.09% | 788.13B | 1.00% | +11.84% | 1.13 |
| Vanguard Total International Stock ETF VXUS | 0.05% | 652.30B | 2.61% | +20.58% | 1.21 |
| Invesco QQQ Trust, Series 1 QQQ | 0.18% | 481.14B | 0.43% | +28.14% | 1.43 |
| Vanguard Growth ETF VUG | 0.03% | 393.80B | 0.39% | +16.85% | 0.99 |
| Vanguard FTSE Developed Markets ETF VEA | 0.03% | 317.30B | 2.60% | +21.64% | 1.23 |
Cheaper alternatives
No fund of the class reaches 60% portfolio overlap — showing the cheapest funds of the class instead.
| Fund | TER | AUM (USD) | Overlap |
|---|---|---|---|
| Invesco QQQ Trust, Series 1 QQQ | 0.18% | 481.14B | 2.6% |
| Vanguard Small-Cap ETF VB | 0.03% | 182.70B | 2.5% |
| Vanguard Value ETF VTV | 0.03% | 245.00B | 1.8% |
| Vanguard Total Stock Market ETF VTI | 0.03% | 2.30T | 1.2% |
| Vanguard Mid-Cap ETF VO | 0.03% | 218.80B | 1.1% |
